



RESEARCH ARTICLE

CELIAC DISEASE AMONG GASTROINTESTINAL PATIENTS IN YEMEN: ITS PREVALENCE, SYMPTOMS AND ACCOMPANYING SIGNS, AND ITS ASSOCIATION WITH AGE AND GENDER

Omar Ahmed Ismael Al-dossary¹ , Redhwan A. Ahmed^{1,2} , Khaled Abdulkareem A Al-Moyed¹ ,
 Azhar Azher Mohammed Al-Ankoshy³ , Mohammed Mohammed Ali Al-Najhi⁴ ,
 Hassan Abdulwahab Al-Shamahy^{1,5}

¹Medical Microbiology and Clinical Immunology Department, Faculty of Medicine and Health Sciences, Sana'a University, Republic of Yemen.

²Laboratory Department, University of Science and Technology Hospital, Sana'a, Yemen.

³Jabir ibn Hayyan Medical University, Faculty of Medicine/Iraq

⁴Orthodontics, Pedodontics and Prevention Department Faculty of Dentistry, Genius University for Sciences & Technology, Dhamar city, Republic of Yemen.

⁵Medical Microbiology department, Faculty of Medicine, Genius University for Sciences & Technology, Dhamar city, Republic of Yemen.

Article Info:



Article History:

Received: 1 August 2021

Reviewed: 5 September 2021

Accepted: 8 October 2021

Published: 15 November 2021

Cite this article:

Al-dossary OAI, Ahmed RA, Al-Moyed KAA, Al-Ankoshy AAM, Al-Najhi MMA, Al-Shamahy HA. Celiac disease among gastrointestinal patients in Yemen: its prevalence, symptoms and accompanying signs, and its association with age and gender. Universal Journal of Pharmaceutical Research 2021; 6(5):1-6.

<https://doi.org/10.22270/ujpr.v6i5.665>

*Address for Correspondence:

Dr. Hassan A. Al-Shamahy, Faculty of Medicine and Health Sciences, Sana'a University, P.O. Box 775 Sana'a, Yemen
 Tel: +967-1-239551; E-mail: shmahe@yemen.net.ye

Abstract

Background and objectives: Celiac disease is a long-standing autoimmune illness that principally affects the small intestine. Typical symptoms comprise digestive problems such as chronic diarrhea, flatulence, malabsorption, loss of appetite, and failure of children to grow normally. The prevalence of celiac disease has not been established in Yemen, either in the general population or in symptomatic patients. Therefore, the current study aimed to assess the prevalence of disease in symptomatic patients and to investigate associated symptoms and signs; and whether prevalence of CD varies greatly between different ages and genders in a hospital in Sana'a.

Methods: A cross sectional study based on the results of serological markers; IgA anti-tissue glutaminase and small bowel biopsies of 600 patients with gastrointestinal symptoms who were all patients who attended in the research period. Data were collected from hospital records during the period from March 2014 to December 2018. Total 600 suspected patients (245 males and 355 females) were subjects and the mean age of \pm SD patients was 30.6 \pm 14.5 years (range 2-92 years).

Results: The prevalence of CD among patients with gastrointestinal symptoms was 9.2%. There was a significant association between CD with females (rate being 11.3%, OR=1.9, $p=0.03$), and 2-19 years age group (21.4% , OR=4.3, $p<0.001$), considering the clinical signs and symptoms there was a significant association between celiac disease and chronic diarrhea (OR=18.4), steatorrhea (OR=9.6), foul odor (OR=8.3), weight loss (OR=5.7), anemia (OR=10.2), abdominal distension (OR=3.1), mouth ulcers (OR=7.2), abdominal bleeding (OR=13.5), diabetes mellitus I (OR=18), and hypothyroidism (OR=79.3).

Conclusions: A high rate of CD was identified among gastrointestinal symptoms patients arriving at the general hospital in Sana'a, Yemen, and this demonstrates the importance of general practitioners in identifying patients with CD, especially in the absence of a medical facility for CD, and this was facilitated through the serological markers test.

Keywords: Celiac disease (CD), prevalence, signs, symptoms, Yemen.

INTRODUCTION

Celiac disease or Coeliac disease (CD), is a continuing autoimmune illness that mainly involves the small

intestine. Typical symptoms comprise digestive problems for instance chronic diarrhea, flatulence, loss of appetite, malabsorption, and failure of children to grow normally. This regularly begins between six

months and two years of age. Non-classical symptoms are more frequent, in particular in people older than two years. Moderate or absent gastrointestinal symptoms may be present, a large number of symptoms relating any part of the body, or no apparent symptoms. CD was first illustrated in childhood; nevertheless, it may arise at all ages. It is also linked with autoimmune diseases, for instance Hashimoto's thyroiditis and type 1 diabetes¹. CD results from a reaction with gluten, which is a group of different proteins found in wheat and other grains such as barley and rye. Moderate amounts of oats, free from pollution with further gluten-containing grains, are regularly tolerated². The incidence of harms may depend on the type of oats. CD appears in people with a genetic predisposition. When exposed to gluten, the abnormal immune response may result in the production of many different auto-antibodies that can involve a number of distinct organs. In the small intestine, this causes an inflammatory reaction and may lead to villous atrophy. This affects the absorption of nutrients, often leading to anemia³. The gold standards in diagnosing CD are bowel biopsy and positive serological markers (anti-tissue IgA (Ttg IgA) antibody and anti-endomysial)¹. HLA class II DQ2 and DQ8 haplotypes are found in nearly all patients with sensitivity of nearly 100% and also in 30% to 40% of the population. On account of a very high negative predictive value, HLA typing can assist and support the exclusion of the diagnosis of CD in ambiguous cases in which the patient not has HLA-DQ2 and DQ8⁴. On the other hand, making the diagnosis is not continuously simple⁵. Often, serum autoantibodies are negative^{4,6}, and many people have only minor changes in the intestine with normal villi. It is reported that many people may have severe symptoms and can be explored for years before a diagnosis is made⁷. Currently, the diagnosis is increasingly being made in people who have no symptoms as a result of screening. However, the evidence regarding the effects of screening is not sufficient to determine its usefulness. While this disease is caused by a persistent intolerance to gluten proteins³, it differs from wheat allergy which is known to be very rare.

Epidemiologically, CD affects about 1 in 100 to 1 in 300 of the world's population¹. This rate may be increased among those at risk; Like first-degree relatives: 1 in 10, or like second-degree relatives: 1 in 39 and 1 in 56 in asymptomatic patients¹. Moreover, the prevalence of CD among unexplained iron deficiency anemia's is 3% to 15%, 2% to 15% among type 1 diabetes, 2% to 7% among hypothyroidism, 3% to 6% among Addison's disease, and autoimmune hepatitis, 3% among irritable bowel syndrome, ataxia, and idiopathic neuropathy¹. Studies in gastroenterology and/or autoimmune diseases are still limited in Yemen and only a few studies have been conducted on autoimmune hepatitis^{9,10} and the relationship between CD and infertility by measuring sex hormones in CD compared to controls healthy¹¹, anti-mannose auto-antibodies in patients with rheumatoid arthritis¹², and intestinal infection among adults and children¹³⁻¹⁵. At present, the only effective treatment is to follow a

gluten-free diet for life. There is no medicine that prevents damage or prevents the body from attacking the intestines when gluten is present. Strict adherence to the diet helps to heal the intestines, which in most cases resolves all symptoms, and depending on when the diet is started, the risk of osteoporosis, bowel cancer and, in some cases, infertility can also be eliminated. Diet can be stressful; failure to comply with the diet may lead to relapse¹⁶. The prevalence of CD has not been established in Yemen, either in the general population or in symptomatic patients. Therefore, the current study aimed to assess the prevalence of disease in symptomatic patients and to investigate associated symptoms and signs; and whether prevalence of CD varies greatly between different ages and genders.

SUBJECTS AND METHODS

Study design and setting

This cross sectional study was conducted at the University of Science and Technology Hospital (USTH) in Sana'a, Yemen. USTH is one of the main hospitals in Yemen, which receives patients from all over the country and also the city of Sana'a is the capital of Yemen. For these factors, the results of this study may represent the whole country.

Data collection

600 symptomatic patients were enrolled in this study. Among them, 245 (40.8%) males and 355 (59.2%) females attended pediatric clinics, internal medicine clinics, and gastroenterology units for medical care in USTH from March 2014 to December 2018. Data were obtained from electronic patient records after approval of the hospital ethics committee. By enzyme-linked immunosorbent assay (ELISA), positive ATtg IgA criteria greater than the ten times of the upper limit of normal (ULN) in children or less than 10 times the ULN but confirmed by small bowel biopsy. Hemoglobin levels (to define anemia based on a hemoglobin concentration less than 11g/dL) were also included. The subjects were divided into categories based on gender and age. Clinical signs, symptoms and other diseases associated with celiac disease were also collected and analyzed.

Data analysis

The whole data were analyzed by IBM SPSS Statistics 22. Ink (International Business Machines Corporation, New York, USA). The outcomes for variables were given in the form of rates (%). Chi Square was used for categorical variables that measured association among categorical variables. *P*-values less than 0.05 were considered significant. Odds of celiac disease (odds ratio, OR) were also analyzed by sex, age groups, symptoms, signs and other syndromes, with 95% *CI*, χ^2 and *p* to test for significance of association with the above factors.

Ethical approval

Ethical approval was obtained from the Ethics Committee from the USTH Sana'a, Yemen.

RESULTS

Table 1 shows the age and gender distribution of patients with gastrointestinal symptoms admitted to the University of Science and Technology Hospital, Sana'a, Yemen - during the period from March 2014 to December 2018 who underwent examination for serological markers; Anti-tissue IgA glutaminase and small intestine biopsies for CD. The percentage of females was 59.2% compared to 40.8% for males. Looking at the age groups, most patients were in the age group 20-40 years (58.2%), followed by 2-19 years (21%) and 41-60 years (18%), while the >60 years group was only 2.8%.

Table 1: Age and gender distribution of patients with intestinal symptoms.

Characters	Number	%	p
Gender			
Male	245	40.8	<0.05
Female	355	59.2	
Age groups			
2-19 years	126	21	<0.05
20-40 years	349	58.2	
41-60 years	108	18	
>60 years	17	2.8	
Total	600	100	30±14.5 years

*significance level less than 0.05 (p).

Table 2 shows the prevalence of serological markers. Anti-tissue IgA glutaminase and small bowel biopsies for CD among different sex and age groups of patients with gastrointestinal symptoms. The prevalence of CD among patients with gastrointestinal symptoms was 9.2%. Considering gender, there was a significant association between celiac disease and females with the rate being 11.3% with an odds ratio equal to 1.9, CI equal to 1.1-3.9 (p=0.03). Considering ages, there was a significant association between celiac disease with 2-19 years as the rate was 21.4% with an odds ratio equal to 4.3, CI equal to 2.4-7.6 (p<0.001), while there was no association between CD and age groups other. Considering the clinical signs and symptoms associated with intestinal symptoms compared to CD (Table 3), there was a significant association between celiac disease and chronic diarrhea (odds ratio=18.4 times), steatorrhea (OR=9.6), foul odor (odds ratio=8.3 times), weight loss (Odds ratio=5.7 times), anemia (odds

ratio=10.2 times), abdominal distension (odds ratio=3.1 times), mouth ulcers (odds ratio=7.2 times), abdominal bleeding (odds ratio=13.5 times), diabetes mellitus I (odds ratio=18 times), and hypothyroidism (odds ratio=79.3 times).

DISCUSSION

CD is an immune condition mediated by systemic disease of the small intestine. Symptoms interrelated to mal-absorption and/or activation of immunity and auto-antibodies to tissue transglutaminase (TTG). CD is distinctive amongst autoimmune diseases in that a generate, dietary gluten, has been recognized, and its removal resolves symptoms and enteropathy in the greater part of patients. Increased knowledge and development of serological tests have led to an increased incidence of disease and a change in the distribution of clinical features¹. In Yemen, its prevalence has not yet been estimated, and current work is an attempt to determine the rate of CD among clinically suspected patients. The prevalence of celiac disease among patients with gastrointestinal symptoms in the current study was 9.2%. Compared with current observations, the prevalence of CD in Yemen exceeds the rate of CD among suspected Finns 5.33% among patients with gastrointestinal symptoms¹⁷ and other previous rates of disease as in Saudi Arabia, South Yorkshire, Amsterdam, the Netherlands and in North America are among the symptoms gastrointestinal representing; 7.6%, 4.7%, 3.0% and 2.0%, respectively¹⁸⁻²¹. On the other hand, results similar to ours were presented by Dickey *et al.*, and Hopper *et al.*,^{22, 23} where the incidence of CD among patients with undiagnosed gastrointestinal symptoms was about 9%. In contrast to the average (9.2%), the prevalence of CD among Iranian patients with irritable bowel syndrome was about 12% and among patients with gastrointestinal symptoms in Italy was about 13% as reported by Shahbazkhani *et al.*, and Carroccio *et al.*, respectively^{24,25}. Considering gender, there was a significant association between CD and females with a rate of 11.3% (OR=1.9 (CI=1.1-3.9, p=0.03) (Table 2). This result is similar to that reported where the incidence of CD is higher in females than in males (17.0 versus 7.8 per 100,000 person-years) in collective analysis²⁶, but this may be for the reason that men are more possible to remain undiagnosed.

Table 2: Serological Markers; Anti-tissue IgA glutaminase and small bowel biopsies for celiac disease among different patients with intestinal symptoms.

Characters	n	Celiac disease n=55		OR	CI 95%	X ²	p
		No	%				
Gender							
Male	n=245	15	6.1	0.5	0.2-0.9	4.6	0.03
Female	n=355	40	11.3	1.9	1.1-3.6	4.6	0.03
Age groups							
2-19 years	n=126	27	21.4	4.3	2.4-7.6	28.8	<0.001
20-40 years	n=349	23	6.6	0.4	0.2-0.8	6.6	0.009
41-60 years	n=108	5	4.6	0.4	0.16-1.1	3.2	0.07
>60 years	n=17	0	0	00	0-1.9	1.7	0.18
Total	n=600	55	9.2				

A systematic review and meta-analysis found a slight increase in seropositivity among women participating in screening studies²⁷ although some studies in adults have found that men and women have the same seroprevalence rates^{28,29}. Men are less likely to undergo duodenal biopsy during upper endoscopy for indications such as diarrhea and weight loss, which may contribute to underdiagnosis³⁰. CD can develop at any age, including the elderly³¹. Considering age in the current study, there was a significant association between celiac disease and age group 2-19 years where the rate was 21.4% with an OR equal to 4.3, CI equal to 2.4-7.6 ($p < 0.001$) (Table 2). This is similar to what has been previously reported where the incidence of CD was higher in the younger age group. This rise in

CD at a young age can be explained by the fact that such diagnoses do not necessarily indicate the late detection of CD long ago - it may result from a de novo loss of gluten tolerance. Studies of serial serum samples have reported loss of gluten tolerance in adulthood³². However, recent prospective cohort studies have found that most patients develop CD before the age of 10 years^{33,34}. Moreover, in the current study, the prevalence of anemia was widespread (71.4%, OR=40.4 times, $p < 0.001$) (Table 3) among ATtg IgA-positive patients in agreement with several studies^{35,36}. These patients are more likely to have acute disease compared to non-anemic CD patients according to Daya, *et al.*,³⁷.

Table 3: Clinical signs and symptoms associated with intestinal symptoms compared to celiac disease patients.

Symptoms and signs	Patients with intestinal symptoms, n=545		Celiac disease, n=55		OR	CI 95%	X ²	p
	No	%	No	%				
Chronic diarrhea	223	40.9	51	92.7	18.4	6.6-56	54	<0.001
Steatorrhea	278	51	50	90.9	9.6	3.7-24.5	32	<0.001
Foul odor	191	35	45	81.8	8.3	4.1-16.9	45	<0.001
Weight loss	376	68.9	51	92.7	5.7	2-16.1	13.7	<0.001
Fatigue	321	58.9	39	70.9	1.7	0.9-3.1	3	0.08
Anemia	31	5.7	39	70.9	40.4	20.3-80.2	206	<0.001
Abdominal pain	447	82.2	49	89	1.8	0.7-4.2	1.7	0.18
Cramping	387	71	41	74.5	1.2	0.6-2.1	0.3	0.55
Abdominal distension	277	50.8	42	76.4	3.1	1.6-5.9	13	<0.001
Mouth ulcers	9	1.7	6	10.9	7.2	2.5-21	17.5	<0.001
Irritable bowel syndrome	169	31	3	5.5	0.12	0.03-0.4	15.9	<0.001
Abdominal bleeding	11	2.02	12	21.8	13.5	5.6-32.5	53.1	<0.001
Abnormal LFT	114	20.9	11	20	0.9	0.4-1.8	0.02	0.87
Diabetes mellitus I	3	0.55	5	9	18	4.1-77.8	27.6	<0.001
Hypothyroidism	1	0.18	7	12.7	79.3	9.5-658	59.7	<0.001

Once serological testing began in the 1990s, there was an expansion of clinical offerings leading to a diagnosis of celiac disease. The proportion of patients with CD who had diarrhea decreased from 73% before 1993 (the year in which serological testing became available at the study site) to 43% thereafter³⁸. Although diarrhea continued to be the most common symptom at presentation, most patients received the diagnosis based on this on other signs or symptoms, such as osteoporosis, anemia, bloating, or irregular bowel habits; some had less common symptoms, including infertility⁹, migraine headaches³⁹ neuropsychiatric symptoms⁴⁰ and abnormal liver enzyme levels⁴¹.

In the current study considering the clinical signs and symptoms associated with intestinal symptoms compared to celiac disease, there was a significant association between celiac disease and chronic diarrhea (OR=18.4), steatorrhea (OR=9.6), foul odor (OR=8.3), weight loss (OR=5.7), anemia (OR=40.4), abdominal distension (OR=3.1), mouth ulcers (OR=7.2), abdominal bleeding (OR=13.5), diabetes mellitus I (OR=18), and hypothyroidism (OR=79.3). These signs and symptoms combined outnumber diarrhea, so diarrhea can no longer be referred to as typical and presentation without diarrhea as atypical. As such, a 2013 consensus statement renamed diarrhea and non-

diarrhea presentations as classic and non-classical celiac disease, respectively⁴². Regardless of the type of symptoms, there is often a long-term delay between the onset of symptoms and a diagnosis of celiac disease. A national survey of patients with celiac disease in the US found the median duration of symptoms to be 11 years before diagnosis⁴³ and a UK study found the median duration to be 4.9 years⁴⁴. In the current study, abnormal LFT occurred in 20% of CD patients, and this is lower than that performed by Castillo *et al.*, as liver biochemical abnormalities were presented in 40% of patients newly diagnosed with celiac disease, according to Castillo *et al.*, series the slight increases observed in aspartate and alanine transaminases are the most common abnormalities⁴¹. The incidence of CD is increasing with its worldwide spread. There is a trend towards an increased diagnosis of non-classical presentations, and there is emerging evidence for accurate non-biopsy diagnosis in selected children³³. Newly developed diagnostic tools, such as the HLA-DQ-based blood test - gluten tetramer, may change the way we diagnose CD in the near upcoming, impending validation and scalability. This technology, combined with validation of serology-based diagnostic algorithms, may bring about an alteration in diagnostic criteria as small bowel biopsy is no longer essential while patients persist to follow a gluten-containing

diet. These changes may convert the roles of gastroenterologists, from diagnosis to management and follow-up⁴⁵. If an evidence-based, biopsy-free strategy is developed for diagnosis, the incidence of celiac disease may increase further and stimulate interventional studies for the prevention of celiac disease in individuals at risk¹.

CONCLUSIONS

The prevalence of CD among Yemeni patients with gastrointestinal disorders was as high as 9.2%, especially among children and adolescents compared to primary care groups elsewhere in the world who reported gastrointestinal symptoms, and the incidence of celiac disease was around 3%. The disease was prevalent among females. On the other hand diagnosis by serological markers is useful in detecting CD in these patients. However, more studies are needed to support and confirm current findings and conclusions. According to this high prevalence, clinicians should pay more attention to CD when examining huge different symptoms especially among women, children and teens to avoid misdiagnosis or long-term delay diagnosis.

ACKNOWLEDGEMENTS

The authors acknowledge the administration of University of Science and Technology Hospital for data supply.

AUTHOR'S CONTRIBUTIONS

Al-dossary OAI: writing original draft, literature survey. **Ahmed RA:** methodology, conceptualization. **Al-Moyed KAA:** formal analysis, review. **Al-Ankoshy AAM:** investigation, data interpretation. **Al-Najhi MMA:** data curation, investigation. **Al-Shamahy HA:** critical review, supervision. All authors revised the article and approved the final version.

DATA AVAILABILITY

The data and material are available from the corresponding author on reasonable request.

CONFLICT OF INTEREST

None to declare.

REFERENCES

- Lebwohl B and Rubio-Tapia A. Epidemiology, presentation, and diagnosis of celiac disease. *Gastroenterology* 2021; 160:63–75. <https://doi.org/10.1053/j.gastro.2020.06.098>
- Pinto-Sánchez MI, Causada-Calo N, Bercik P, et al. Safety of adding oats to a gluten-free diet for patients with celiac disease: systematic review and meta-analysis of clinical and observational studies. *Gastroenterol* 2017; 2153 (2): 395–409.e3. <https://doi.org/10.1053/j.gastro.2017.04.009>
- Tovoli F, Masi C, Guidetti E, et al. Clinical and diagnostic aspects of gluten related disorders. *World J Clin Cases* 2015; 3 (3): 275-84.

- <https://doi.org/10.12998/wjcc.v3.i3.275>. *PMC 4360499*
- Lewis NR, Scott BB. Systematic review: the use of serology to exclude or diagnose coeliac disease (a comparison of the endomysial and tissue transglutaminase antibody tests). *Alimentary Pharmacol Therap* 2006; 24(1): 47–54. <https://doi.org/10.1111/j.1365-2036.2006.02967.x>
- Matthias T, Pfeiffer S, Selmi C, Eric Gershwin M. Diagnostic challenges in celiac disease and the role of the tissue transglutaminase-neo-epitope. *Clin Rev Allergy Immunol* 2010; 38 (2–3): 298–301. <https://doi.org/10.1007/s12016-009-8160-z>
- Molina-Infante J, Santolaria S, Sanders DS, Fernández-Bañares F. Systematic review: noncoeliac gluten sensitivity. *Alimentary Pharmacol Therap (Review)* 2015; 41 (9): 807–20. <https://doi.org/10.1111/apt.13155>
- Ludvigsson JF, Card T, Ciclitira PJ, Swift GL, Nasr I, Sanders DS, Ciacci C. Support for patients with celiac disease: A literature review. *United Europ Gastroenterol J (Review)* 2015; 3 (2): 146–59. <https://doi.org/10.1177/2050640614562599>
- Burkhardt JG, Chapa-Rodríguez A, Bahna SL. Gluten sensitivities and the allergist: Threshing the grain from the husks. *Allergy* 2018; 73 (7): 1359–1368. <https://doi.org/10.1111/all.13354>
- Othman A, Alyosfi E, AL-Shamahy H. The association of epstein-barr virus antibodies with rheumatoid arthritis among Yemeni patients in Sana'a city. *Universal J Pharm Res* 2017; 2(4). <https://doi.org/10.22270/ujpr.v2i4.R4>
- Othman A, Hamzah E, Almughales J, Al-Mikhlaify A. Serum positivity of ana and asma among khat and nonkhat chewers as markers for autoimmune hepatitis type 1. *Universal J Pharm Res* 2017; 2(4), July 2017. <https://doi.org/10.22270/ujpr.v2i4.R5>
- Al-Anesi M, Hu Q, Al-Eryani E, Al-Amrani M, Al-Shamahy H. The association of adult male and female infertility with celiac disease patients in Yemen. *Universal J Pharm Res* 2017; 2(6): 21-23. <http://doi.org/10.22270/ujpr.v2i6.R5>
- El-Aghbary D, Al-Jaaidi A, Al-Moyed K, Al-Robasi AA, Othman A. Seroprevalence of anti-mannose binding lectin autoantibodies in patients with rheumatoid arthritis in Sana'a city- Yemen. *Universal J Pharm Res* 2018; 3(2):34-37. <https://doi.org/10.22270/ujpr.v3i2.138>
- Al-Shamahy HA, Ishak AA. Trends and causes of morbidity in part of children in the city of Sana'a, Yemen 1978-2018: findings of single children's health center. *Universal J Pharm Res* 2021; 5(6). <https://doi.org/10.22270/ujpr.v5i6.504>
- Shamsan ENA, De-ping C, Al-Shamahy HA, et al. Coccidian intestinal parasites among children in Al-Torbah city in Yemen: in country with high incidence of malnutrition. *Universal J Pharm Res* 2019; 4(4). <https://doi.org/10.22270/ujpr.v4i4.301>
- Sheiban A, Al-Shamahy H, Alattab N, Abbas AK. Epidemicity of *Vibrio cholera* in Sana'a city, Yemen: prevalence and potential determinants. *Universal J Pharm Res* 2018; 2(6). <https://doi.org/10.22270/ujpr.v2i6.R1>
- Kupper C. Dietary guidelines and implementation for celiac disease. *Gastroenterol* 2005, 128 (4 Suppl 1): S121–7. <https://doi.org/10.1053/j.gastro.2005.02.024>
- Collin P, Rasmussen M, Kyrönpalo S, et al., The hunt for coeliac disease in primary care. *QJM* 2002; 95(2):75-77. <https://doi.org/10.1093/qjmed/95.2.75>
- Al Attas RA. How common is celiac disease in Eastern Saudi Arabia. *Ann Saudi Med* 2002; 22(5-6):315-319. <https://doi.org/10.5144/0256-4947.2002.315>
- Sanders DS, Patel D, Stephenson TJ, et al., A primary care cross-sectional study of undiagnosed adult coeliac disease. *European J Gastroenterol Hepatol* 2003; 15(4): 407-413. <https://doi.org/10.1097/00042737-200304000-00012>
- Hadithi M, Mary E von Blomberg, Crusius JBA, et al., Accuracy of serologic tests and HLA-DQ typing for

- diagnosing celiac disease. *Annals Internal Med* 2007; 147(5): 294-302. <https://doi.org/10.7326/0003-4819-147-5-200709040-00003>
21. Catassi C, Kryszak D, Louis-Jacques O, et al., Detection of celiac disease in primary care: a multicenter case-finding study in North America. *The American J Gastroenterol* 2007; 102(7):1454. <https://doi.org/10.1111/j.1572-0241.2007.01173.x>
 22. Dickey W, McMillan S, Hughes D. Identification of coeliac disease in primary care. *Scandinavian J Gastroenterol* 1998; 33(5): 491-493. <https://doi.org/10.1136/bmj.318.7177.164>
 23. Hopper AD, Cross SC, McAlindon ME, et al. Pre-endoscopy serological testing for coeliac disease: evaluation of a clinical decision tool. *BMJ* 2007; 334(7596): 729. <https://doi.org/10.1136/bmj.39133.668681.BE>
 24. Shahbakhani B, Forootan M, Merat S, et al. Coeliac disease presenting with symptoms of irritable bowel syndrome. *Alimentary Pharmacol Therap* 2003; 18(2):231-235. <http://dx.doi.org/10.1046/j.1365-2036.2003.01666.x>
 25. Carroccio A, Vitale G, Di Prima L, et al. Comparison of anti-transglutaminase ELISAs and an anti-endomysial antibody assay in the diagnosis of celiac disease: a prospective study. *Clinical Chem* 2002; 48(9): 1546-1550. <https://doi.org/10.1093/clinchem/48.9.1546>
 26. King JA, Jeong J, Underwood FE, et al. Incidence of celiac disease is increasing over time: a systematic review and meta-analysis. *Am J Gastroenterol* 2020; 115:507–525. <http://dx.doi.org/10.14309/ajg.0000000000000523>
 27. Jansson-Knodell CL, Hujoel IA, West CP, et al. Sex difference in celiac disease in undiagnosed populations: a systematic review and meta-analysis. *Clin Gastroenterol Hepatol* 2019; 17:1954–1968. <https://doi.org/10.1016/j.cgh.2018.11.013>
 28. Rubio-Tapia A, Kyle RA, Kaplan EL, et al. Increased prevalence and mortality in undiagnosed celiac disease. *Gastroenterol* 2009; 137:88–93. <https://doi.org/10.1053/j.gastro.2009.03.059>
 29. Katz KD, Rashtak S, Lahr BD, et al. Screening for celiac disease in a North American population: sequential serology and gastrointestinal symptoms. *Am J Gastroenterol* 2011; 106:1333–1339. <https://doi.org/10.1038/ajg.2011.21>
 30. Lebwohl B, Tennyson CA, Holub JL, et al. Sex and racial disparities in duodenal biopsy to evaluate for celiac disease. *Gastrointest Endosc* 2012; 76:779–785. <https://doi.org/10.1016/j.gie.2012.05.011>
 31. Collin P, Vilppula A, Luostarinen L, et al. Review article: coeliac disease in later life must not be missed. *Aliment Pharmacol Ther* 2018;47:563–572. <https://doi.org/10.1111/apt.14490>
 32. Catassi C, Kryszak D, Bhatti B, et al. Natural history of celiac disease autoimmunity in a USA cohort followed since 1974. *Ann Med* 2010; 42:530–538. <https://doi.org/10.3109/07853890.2010.514285>
 33. Liu E, Dong F, Barón AE, et al. High incidence of celiac disease in a long-term study of adolescents with susceptibility genotypes. *Gastroenterol* 2017;152:1329–1336. <https://doi.org/10.1053/j.gastro.2017.02.002>
 34. Andrén Aronsson C, Lee H-S, Hård Af Segerstad EM, et al. Association of gluten intake during the first 5 years of life with incidence of celiac disease autoimmunity and celiac disease among children at increased risk. *JAMA* 2019; 322(6):514–523. <https://doi.org/10.1001/jama.2019.10329>
 35. Fasano A, Catassi C. Current approaches to diagnosis and treatment of celiac disease: an evolving spectrum. *Gastroenterol* 2001; 120(3): 636-651. <https://doi.org/10.1053/gast.2001.22123>
 36. Lasa J, Olivera L, Soifer R, Moore, et al., Iron-deficiency anemia as a subclinical celiac disease presentation in an Argentinian population. *Revista de Gastroenterología de México (English Edition)*, 2017; 82(3): 270-273. <https://doi.org/10.1016/j.rgm.2016.12.008>
 37. Daya HA, Lebwohl B, Lewis SK, et al. Celiac disease patients presenting with anemia have more severe disease than those presenting with diarrhea. *Clin Gastroenterol Hepatol* 2013; 11(11):1472-1477. <https://doi.org/10.1016/j.cgh.2013.05.030>
 38. Lo W, Sano K, Lebwohl B, et al. Changing presentation of adult celiac disease. *Dig Dis Sci* 2003; 48:395-398. <https://doi.org/10.1023/a:1021956200382>
 39. Lebwohl B, Roy A, Alaedini A, et al. Risk of headache related healthcare visits in patients with celiac disease: a population-based observational study. *Headache* 2016; 56:849-858. <https://doi.org/10.1111/head.12784>
 40. Zingone F, Swift GL, Card TR, et al. Psychological morbidity of celiac disease: a review of the literature. *United European Gastroenterol J* 2015; 3:136-145. <https://doi.org/10.1177/2050640614560786>
 41. Castillo NE, Vanga RR, Theethira TG, et al. Prevalence of abnormal liver function tests in celiac disease and the effect of a gluten-free diet in the US population. *Am J Gastroenterol* 2015; 110:1216-222. <https://doi.org/10.1038/ajg.2015.192>
 42. Ludvigsson JF, Leffler DA, Bai JC, et al. The Oslo definitions for coeliac disease and related terms. *Gut* 2013; 62:43-52. <https://doi.org/10.1136/gutjnl-2011-301346>
 43. Green P, Stavropoulos S, Panagi SG, Goldstein S. Characteristics of adult celiac disease in the USA: results of a national survey. *Am J Gastroenterol* 2001; 96:126-131. <https://doi.org/10.1111/j.1572-0241.2001.03462.x>
 44. Sanders DS. Changing face of adult coeliac disease: experience of a single university hospital in South Yorkshire. *Postgrad Med J* 2002; 78(915):31-33. <https://doi.org/10.1136/fpmj.78.915.31>
 45. van der Windt DA, Jellema P, Mulder CJ, Kneepkens CM, van der Horst HE. "Diagnostic testing for celiac disease among patients with abdominal symptoms: a systematic review. *JAMA* 2010; 303 (17): 1738–46. <https://doi.org/10.1001/jama.2010.549>